相关实验视频
Updated: May 15, 2025

09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
6.6K
梅托拉和阿佐塞米德,临床上使用的利尿剂,表现出抑制格里奥沙I的抑制活性
Masahiro Watanabe1, Takao Toyomura1, Hidenori Wake2
1Department of Pharmacology, School of Pharmacy, Shujitsu University, Okayama, Japan.
Biotechnology and applied biochemistry
|April 9, 2025
概括
某些利尿剂,如美托拉和阿佐塞米德,抑制了清除甲基醇 (MGO) 的酶 - - 氧酶I (GLO1). 这种抑制可以导致MGO衍生先进糖化最终产品 (AGEs) 的积累,可能会影响细胞健康.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 甲基醇 (MGO) 是糖解的细胞毒性副产物,形成高级糖化最终产物 (AGEs).
- 甘氨酸酶I (GLO1) 对于MGO排毒至关重要,其抑制可以导致MGO积累.
- 昆,一种利尿剂,以前被发现可以抑制GLO1活性.
研究的目的:
- 调查结构上类似于化的利尿剂是否也抑制GLO1活性.
- 为了确定GLO1抑制性利尿剂对细胞增殖和MGO衍生的AGE积累的影响.
主要方法:
- 对复合GLO1.1的利尿抑制活性的光谱光度测定.
- MTT测定用于评估细胞增殖.
- 西方涂抹以评估MGO衍生的AGE积累.
主要成果:
- 梅托拉和阿佐塞米德显著抑制了GLO1活性 (97%在100μM).
- 最小的抑制结构被确定为quinazolinone (metolazone) 和phenyltetrazole (azosemide). 这两种药物具有较小的抑制作用.
- 这些利尿剂降低了细胞增殖,并在HK-2和EA.hy926细胞中增加了MGO衍生的AGE.
结论:
- 梅托拉和阿佐塞米德对GLO1.1具有抑制作用.
- 这些利尿剂的临床使用,特别是高剂量或长时间使用,可能会通过GLO1抑制和随后的MGO/AGE积累促进病原发生.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
Oral Hypoglycemic Agents: Sulfonylureas
165
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
165
Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112
Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
9.7K
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
9.7K

